27 August 07:30 - 27 August 09:00
Japan and China are the world's second and third largest markets for health care including pharmaceutical sales. Research and life science is heavly invested in, and both countries are looking for new projects or products to acquire or in-license from west, especially Europe as company and project valuations and prices in general are much lower thean in the US.
In Japan and China, there are many opportunities for both small and large companies to find new partners, get financing, and speed up development in order achieve commercial success faster. Welcome to a breakfast seminar where Björn Hammarberg, ABD Life Sciences Ltd (ABD) in Hong Kong and Johan Westblad, Aurora Partners KK (Aurora) in Tokyo, Japan will shatter some myths and confirm others.
Examples will illustrate how partnerships and solutions from China and Japan to help Swedish companies to get ahead in their commercial or technical development. For example, development projects can be partly financed through outlicensing and thereby get access to larger patient base or increase the value of the project is to include Japan in their clinical development programs. Today, many people are unaware of how quickly one can now do clinical trials in Japan and get approval, if you know how and are well prepared.
When: August 27, 2015, at 08.00-09.00 (breakfast is served from 07.45)
Where: Wenner-Gren Center, Sveavägen 166, floor 24 (take the elevators to floor 23)
The registration is closed, please contact anna.frejd@ssci.se if you are interested in participating.
Cancellation to anna.frejd@ssci.se.
Registrering